The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials. Patients and Methods: KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care (BSC). We tested whether the effect of panitumumab on progression-free survival (PFS) differed by KRAS status. Results: KRAS status was ascertained in 427 (92%) of 463 patients (208 panitumumab, 219 BSC). KRAS mutations were found in 43% of patients. The treatment effect on PFS in the wild-type (WT) KRAS group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P < .0001) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3 weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and 0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival (HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined). Consistent with longer exposure, more grade III treatment-related toxicities occurred in the WT KRAS group. No significant differences in toxicity were observed between the WT KRAS group and the overall population. Conclusion: Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors. KRAS status should be considered in selecting patients with mCRC as candidates for panitumumab monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux®) in metastatic colorectal cancer (mCRC).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Amado et al., 2008
Experimental — accuracy not yet measuredIn the citing paper
“Patients must have KRAS wt tumors for panitumumab to be effective [22,23].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [22]
In the citing paper
“Although exclusion of patients with KRAS (exon 2)-mutant tumors has arithmetically increased the percentage of responders up to 13–17 %”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [32]
In the citing paper
“most KRAS wild-type tumors still do not respond to anti-EGFR moAbs [26, 32].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationMoore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
Newton, C. R., Graham, A., Heptinstall, L., Powell, S. J., Summers, C. W., Kalsheker, N. A., Smith, J. C., & Markham, A. F. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.7.2503 · Cited by 2,483
Cited by
Sorted by citations
Items 901–1,000 of 1,014
Stefano, A. D. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9732 · Cited by 45
Bernards, R. (2010) · Cell · doi:10.1016/j.cell.2010.03.018 · Cited by 43
Molecular Testing in Colorectal Cancer
Shi, C., & Washington, K. M. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpi83dinulujni · Cited by 43
Danese, E., Minicozzi, A. M., Benati, M., Montagnana, M., Paviati, E., Salvagno, G. L., Lima-Oliveira, G., Gusella, M., Pasini, F., Lippi, G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126417 · Cited by 43
Current biologics for treatment of biliary tract cancers
Zhao, D. Y., & Lim, K. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.05.04 · Cited by 42
The New Genetic Landscape of Cushing’s Disease: Deubiquitinases in the Spotlight
Sbiera, S., Kunz, M., Weigand, I., Deutschbein, T., Dandekar, T., & Faßnacht, M. (2019) · Cancers · doi:10.3390/cancers11111761 · Cited by 43
Current Understanding of Urachal Adenocarcinoma and Management Strategy
Claps, M., Stellato, M., Zattarin, E., Mennitto, A., Sepe, P., Guadalupi, V., Mennitto, R., de Braud, F., Verzoni, E., & Procopio, G. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0878-z · Cited by 45
Bours, M. J. L. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.01.022 · Cited by 46
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients
Malapelle, U., Passiglia, F., Cremolini, C., Reale, M. L., Pepe, F., Pisapia, P., Avallone, A., Cortinovis, D. L., Stefano, A. D., Fassan, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.015 · Cited by 43
Raoul, J., Laethem, J. V., Peeters, M., Brézault, C., Husseini, F., Cals, L., Nippgen, J., Loos, A., & Rougier, P. R. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-112 · Cited by 43
Self-citationHoyle, M., Peters, J., Crathorne, L., Jones-Hughes, T., Cooper, C., Napier, M., & Hyde, C. (2013) · Value in Health · doi:10.1016/j.jval.2012.11.001 · Cited by 43
The Role of Targeting Mammalian Target of Rapamycin in Lung Cancer
Pal, S. K., Figlin, R. A., & Reckamp, K. L. (2008) · Clinical Lung Cancer · doi:10.3816/clc.2008.n.049 · Cited by 43
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
Aleksakhina, S. N., & Imyanitov, E. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010931 · Cited by 41
Johnson, R. M., Qu, X., Lin, C.-F., Huw, L.-Y., Venkatanarayan, A., Sokol, E., Ou, F.-S., Ihuegbu, N., Zill, O. A., Kabbarah, O., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33172-5 · Cited by 42
Pharmacogenomics and Stratified Medicine
Padmanabhan, S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00001-3 · Cited by 42
The inhibitory effects of 5‐hydroxy‐3,6,7,8,3′,4′‐hexamethoxyflavone on human colon cancer cells
Qiu, P., Guan, H., Dong, P., Guo, S., Zheng, J., Li, S., Chen, Y., Ho, C., Pan, M., McClements, D. J., et al. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100070 · Cited by 42
Molecular Predictors of Response to Chemotherapy in Colorectal Cancer
Dienstmann, R., Vilar, E., & Tabernero, J. M. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318212f844 · Cited by 43
Lamas, M. J., Duran, G., Balboa, E., Bernárdez, B., Touris, M., Vidal, Y., Gallardo, E., López‐López, R., Carracedo, Á., & Barros, F. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.196 · Cited by 42
Cushman‐Vokoun, A. M., Stover, D. G., Zhao, Z., Koehler, E., Berlin, J. D., & Vnencak‐Jones, C. L. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.04.005 · Cited by 42
A statistician's perspective on biomarkers in drug development
Jenkins, M. A., Flynn, A. A., Smart, T. S., Harbron, C. G., Sabin, T., Ratnayake, J., Delmar, P., Herath, A., Jarvis, P., Matcham, J., et al. (2011) · Pharmaceutical Statistics · doi:10.1002/pst.532 · Cited by 43
Current and advancing treatments for metastatic colorectal cancer
Sanz‐García, E., Grasselli, J., Argilés, G., Elez, M. E., & Tabernero, J. M. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1108405 · Cited by 42
A Comprehensive Overview of Colon Cancer- A Grim Reaper of the 21st Century
Kumar, R., Harilal, S., Carradori, S., & Mathew, B. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666201026143757 · Cited by 44
Role of thyroid hormone-integrin αvβ3-signal and therapeutic strategies in colorectal cancers
Yang, Y.-C. S. H., Ko, P.-J., Pan, Y.-S., Lin, H., Whang‐Peng, J., Davis, P. J., & Wang, K. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00719-5 · Cited by 46
Wu, S., Gan, Y., Wang, X., Liu, J., Li, M., & Tang, Y. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1400-x · Cited by 44
Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer
Milano, G. A., Étienne-Grimaldi, M.-C., Dahan, L., Francoual, M., Spano, J., Benchimol, D., Chazal, M., Létoublon, C., André, T., Gilly, F. N., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn416 · Cited by 41
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
Patelli, G., Mauri, G., Tosi, F., Amatu, A., Bencardino, K. B., Bonazzina, E. F., Pizzutilo, E. G., Villa, F., Calvanese, G., Agostara, A. G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0079 · Cited by 44
Self-citationGenetic profiles of cervical tumors by high‐throughput sequencing for personalized medical care
Müller, E., Brault, B., Holmes, A. M., Legros, A., Jeannot, E., Campitelli, M., Rousselin, A., Goardon, N., Frébourg, T., Krieger, S., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.492 · Cited by 40
Mitchell, E. P., Piperdi, B., Lacouture, M. E., Shearer, H., Iannotti, N. O., Pillai, M. V., Xu, F., & Yassine, M. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.06.004 · Cited by 41
Relevance of systems pharmacology in drug discovery
Cucurull-Sanchez, L., Spink, K. G., & Moschos, S. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.015 · Cited by 42
Anaplastic Thyroid Cancer: Outcome and the Mutation/Expression Profiles of Potential Targets
Wu, H., Sun, Y., Ye, H., Yang, S., Lee, S. L., & Morenas, A. D. L. (2015) · Pathology & Oncology Research · doi:10.1007/s12253-014-9876-5 · Cited by 41
Ausch, C., Buxhofer‐Ausch, V., Oberkanins, C., Holzer, B., Minai-Pour, M., Jahn, S. W., Dandachi, N., Zeillinger, R., & Kriegshäuser, G. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.090022 · Cited by 41
Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer
Corte, C. M. D., Fasano, M., Papaccio, F., Ciardiello, F., & Morgillo, F. (2014) · Biomedicines · doi:10.3390/biomedicines2040345 · Cited by 41
Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies
Nedergaard, M. K., Hedegaard, C. J., & Poulsen, H. S. (2012) · BioDrugs · doi:10.2165/11599760-000000000-00000 · Cited by 40
Lin, A. Y., Buckley, N. S., Lu, A.-T. T., Kouzminova, N. B., & Salpeter, S. R. (2011) · Clinical Colorectal Cancer · doi:10.3816/ccc.2011.n.009 · Cited by 45
Díaz‐Rubio, E., Gómez‐España, A., Massutí, B., Sastre, J., Reboredo, M., Manzano, J. L., Rivera, F., Safont7, M., Montagut, C. O., González‐Flores, E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047345 · Cited by 41
EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects
Pérez, R., Moreno, E., Garrido, G., & Crombet, T. (2011) · Cancers · doi:10.3390/cancers3022014 · Cited by 41
Amatu, A., Barault, L., Moutinho, C., Cassingena, A., Bencardino, K. B., Ghezzi, S., Palmeri, L., Bonazzina, E. F., Tosi, F., Ricotta, R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw071 · Cited by 40
Self-citationTernès, N., Rotolo, F., Heinze, G., & Michiels, S. (2016) · Biometrical Journal · doi:10.1002/bimj.201500234 · Cited by 41
Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer
Shimada, Y., Yagi, R., Kameyama, H., Nagahashi, M., Ichikawa, H., Tajima, Y., Okamura, T., Nakano, M., Nakano, M., Sato, Y., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.02.004 · Cited by 41
Neurological complications of new chemotherapy agents
Zukas, A. M., & Schiff, D. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox115 · Cited by 43
Lin, C., Yang, S., Peng, C., & Shieh, M. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b13431 · Cited by 42
Moradi‐Kalbolandi, S., Hosseinzade, A., Salehi, M., Merikhian, P., & Farahmand, L. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12911 · Cited by 42
Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis
Poudel, K. R., Roh‐Johnson, M., Su, X. A., Ho, T. T. G., Mathsyaraja, H., Anderson, S., Grady, W. M., Moens, C. B., Conacci‐Sorrell, M., Eisenman, R. N., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.05.021 · Cited by 39
Carotenuto, P., Roma, C., Rachiglio, A. M., Tatangelo, F., Pinto, C., Ciardiello, F., Nappi, O., Iaffaioli, V. R., Botti, G., & Normanno, N. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.86 · Cited by 41
Optimizing the synthesis of clinical trial data using sequential trees
Emam, K. E., Mosquera, L., & Zheng, C. (2020) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocaa249 · Cited by 41
Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
Araujo, L. H., Souza, B. M., Leite, L. R., Parma, S. A. F., Lopes, N. P., Malta, F. S. V., & Freire, M. C. M. (2021) · BMC Cancer · doi:10.1186/s12885-021-07884-8 · Cited by 41
Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer
Janssen, J. B. E., Medema, J. P., Gootjes, E. C., Tauriello, D. V. F., & Verheul, H. M. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102433 · Cited by 42
Erve, I. V. ’., Medina, J. E., Leal, A., Papp, E., Phallen, J. A., Adleff, V., Chiao, E. J., Arun, A. S., Bolhuis, K., Simmons, J. K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2538 · Cited by 47
Oltedal, S., Aasprong, O. G., Møller, J. H., Kørner, H., Gilje, B., Tjensvoll, K., Birkemeyer, E., Reino Heikkilä, A., Smaaland, R., & Nordgård, O. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1233-5 · Cited by 41
KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer
Jimeno, A., Messersmith, W. A., Hirsch, F. R., Franklin, W. A., & Eckhardt, S. G. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e31819e3202 · Cited by 39
Reverse Phase Protein Arrays: Mapping the Path Towards Personalized Medicine
Gallagher, R. I., & Espina, V. A. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0122-3 · Cited by 40
Ferreira, C. G., Aran, V., Zalcberg-Renault, I., Victorino, A. P., Salem, J. H., Bonamino, M., Vieira, F. M. D. A. C., & Zalis, M. G. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-73 · Cited by 41
Dobi, E., Monnien, F., Kim, S. C. H., Ivanaj, A., N'Guyen, T., Demarchi, M., Adotévi, O., Thiery-Vuillemin, A., Jary, M., Kantelip, B. M., et al. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2012.09.002 · Cited by 43
Novel Immunotherapeutic Strategies of Gastric Cancer Treatment
Amedei, A., Benagiano, M., Bella, C. D., Niccolai, E., & D’Elios, M. M. (2011) · BioMed Research International · doi:10.1155/2011/437348 · Cited by 43
EGFR Antibodies in Colorectal Cancer: Where Do They Belong?
Grothey, A. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.3407 · Cited by 41
New structural and functional insight into the regulation of Ras
Kano, Y., Cook, J. D., Lee, J. E., & Ohh, M. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.006 · Cited by 38
Wang, Z., Gao, Q., & Fang, J. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1886-y · Cited by 43
The Multidisciplinary Management of Rectal Cancer
Meredith, K. L., Hoffe, S. E., & Shibata, D. (2009) · Surgical Clinics of North America · doi:10.1016/j.suc.2008.09.021 · Cited by 40
Odom, D. M., Barber, B., Bennett, L., Peeters, M., Zhao, Z., Kaye, J. A., Wolf, M., & Wiezorek, J. S. (2010) · International Journal of Colorectal Disease · doi:10.1007/s00384-010-1112-5 · Cited by 40
Self-citationPromoter CpG Island Methylation Markers in Colorectal Cancer: The Road Ahead
Draht, M. X. G., Riedl, R. G., Niessen, H. E. C., Carvalho, B. G., Meijer, G. A., Herman, J. G., van Engeland, M., Melotte, V., & Smits, K. M. (2012) · Epigenomics · doi:10.2217/epi.12.9 · Cited by 40
Pešek, M., Benešová, L., Belšánová, B., Mukenšnábl, P., Bruha, F., & Minárik, M. (2009) · PubMed · Cited by 40
KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer
Herreros‐Villanueva, M., Rodrigo, M., Claver, M., Múñiz, P., Lastra, E., Girón, C. G., & del Corral, M. J. C. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0232-x · Cited by 41
Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling
Owusu, B. Y., Bansal, N., Venukadasula, P. K. M., Ross, L. J., Messick, T. E., Goel, S., Galemmo, R. A., & Klampfer, L. (2016) · Oncotarget · doi:10.18632/oncotarget.8785 · Cited by 40
Emerging Systemic Therapies for Colorectal Cancer
Krauss, J. C., & Veenstra, C. M. (2018) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0037-1602238 · Cited by 41
Fos-like antigen 2 (FOSL2) promotes metastasis in colon cancer
Li, S., Fang, X., Wang, X., & Fei, B. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.08.016 · Cited by 40
Hedgehog Signaling in Colorectal Cancer: All in the Stroma?
Geyer, N., & Gerling, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031025 · Cited by 40
Fan, X., Wan, X., Fu, X., Wu, P., Chen, D., Wang, P.-N., Li, J., Wang, D., Chen, Z., Huang, Y. J., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2320-3 · Cited by 40
Advances in the Treatment of Metastatic Colorectal Cancer
Kurkjian, C. D., & Kummar, S. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181907ed9 · Cited by 41
Price, T. J., Bruhn, M. A., Lee, C. K., Hardingham, J. E., Townsend, A. R., Mann, K. P., Simes, J., Weickhardt, A., Wrin, J. W., Wilson, K., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.37 · Cited by 39
Loree, J. M., Wang, Y., Syed, M. A., Sorokin, A. V., Coker, O., Xiu, J., Weinberg, B. A., Vanderwalde, A. M., Tesfaye, A., Raymond, V. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0180 · Cited by 43
Characterization of Genomic Alterations in Colorectal Liver Metastasis and Their Prognostic Value
Bao, X., Wang, K., Liu, M., Li, B., Wang, H., Jin, K., Yan, X., Zhang, H., Bao, Q., Xu, D., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.760618 · Cited by 40
Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
Ríos-Hoyo, A., Monzonís, X., Vidal, J., Linares, J., & Montagut, C. O. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1398419 · Cited by 41
Current and Future Therapies for Advanced Gastric Cancer
Davidson, M., Okines, A. F. C., & Starling, N. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.05.013 · Cited by 39
Kelley, R. K., Bebber, S. L. V., Phillips, K. A., & Venook, A. P. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0004 · Cited by 40
Targeted Inhibition of Kinases in Cancer Therapy
Baker, S. J., & Reddy, E. P. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20220 · Cited by 39
Challenges Posed to Pathologists in the Detection of KRAS Mutations in Colorectal Cancers
Dudley, J. C., Tseng, L., Rooper, L. M., Harris, M., Haley, L. M., Chen, G., Gocke, C. D., Eshleman, J. R., & Lin, M. (2015) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0649-oa · Cited by 39
Jesinghaus, M., Wolf, T. A., Pfarr, N., Muckenhuber, A., Ahadova, A., Warth, A., Goeppert, B. F., Sers, C., Kloor, M., Endris, V., et al. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000423 · Cited by 39
Song, Y., Zhang, Y., & Wang, T. (2012) · Small · doi:10.1002/smll.201202242 · Cited by 39
Manzari, M. T., Rosalia, E. K., Chen, T. F., Wittrup, K. D., & Spangler, J. B. (2012) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 39
Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
Okines, A. F. C., de Castro, D. G., Cunningham, D., Chau, I., Langley, R. E., Thompson, L. C., Stenning, S. P., Saffery, C., Barbáchano, Y., Coxon, F. Y., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.007 · Cited by 39
Targeted Therapy in Older Patients With Solid Tumors
Kelly, C. M., Power, D. G., & Lichtman, S. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4246 · Cited by 39
Sag, A. A., Selçukbırıcık, F., & Mandel, N. M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i11.3127 · Cited by 40
Current and future biomarkers in the treatment of colorectal cancer
Cuyle, P.-J. A., & Prenen, H. (2016) · Acta Clinica Belgica · doi:10.1080/17843286.2016.1262996 · Cited by 40
Yao, J., Zang, W., Ge, Y., Weygant, N., Yu, P., Li, L., Rao, G., Jiang, Z., Yan, R., He, L., et al. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/4248971 · Cited by 40
Mei, Z., Shao, Y. W., Lin, P., Cai, X., Wang, B., Ding, Y., Ma, X., Wu, X., Xia, Y., Zhu, D., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4298-5 · Cited by 39
Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments
Ji, J., Wang, C., & Fakih, M. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s340392 · Cited by 39
In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging
Yosef, H. K., Mavarani, L., Maghnouj, A., Hahn, S. A., El‐Mashtoly, S. F., & Gerwert, K. B. (2015) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-015-8875-z · Cited by 40
Wilson, M. A., Zhao, F., Khare, S., Roszik, J., Woodman, S. E., D'Andrea, K. P., Wubbenhorst, B. S., Rimm, D. L., Kirkwood, J. M., Kluger, H. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1162 · Cited by 39
Belmont, P. J., Jiang, P., McKee, T. D., Xie, T., Isaacson, J., Baryla, N. E., Roper, J., Sinnamon, M. J., Lee, N. V., Kan, J. L. C., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005516 · Cited by 39
Berry, W., Algar, E. M., Kumar, B., Desmond, C., Swan, M. P., Jenkins, B. J., & Croagh, D. G. (2017) · International Journal of Cancer · doi:10.1002/ijc.30648 · Cited by 40
Medici, B., Riccò, B., Caffari, E., Zaniboni, S., Salati, M., Spallanzani, A., Garajová, I., Benatti, S., Chiavelli, C., Dominici, M., et al. (2023) · Cancers · doi:10.3390/cancers15133509 · Cited by 43
Tie, J., & Desai, J. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0330-0 · Cited by 38
Custodio, A., Barriuso, J., de Castro, J., Martínez-Marín, V., Moreno, V., Rodrı́guez-Salas, N., & Feliú, J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.02.004 · Cited by 38
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer
Sameen, S., Barbuti, R., Milazzo, P., Cerone, A., Re, M. D., & Danesi, R. (2015) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2015.10.019 · Cited by 41
Cancer Concepts and Principles: Primer for the Interventional Oncologist—Part I
Hickey, R., Vouche, M., Sze, D. Y., Hohlastos, E. S., Collins, J. D., Schirmang, T., Memon, K., Ryu, R. K., Sato, K. T., Chen, R., et al. (2013) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2013.04.024 · Cited by 38
Current status of experimental therapeutics for head and neck cancer
Lee, J., & Moon, C. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2010.010354 · Cited by 38
RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer
Waring, P. M., Tie, J., Maru, D. M., & Karapetis, C. S. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.10.006 · Cited by 41
Hepatic metastasis from colorectal cancer
Aloia, T. A., & Vauthey, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-34062-5.00092-3 · Cited by 38
Baas, J. M., Krens, L. L., ten Tije, A. J., Erdkamp, F., van Wezel, T., Morreau, H., Gelderblom, H. A. J., & Guchelaar, H. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0285-8 · Cited by 38
Sato, K., Shin, M., Sakimura, A., Zhou, Y., Tanaka, T., Kawanishi, M., Kawasaki, Y., Yokoyama, S., Koizumi, K., Saiki, I., et al. (2013) · Cancer Science · doi:10.1111/cas.12225 · Cited by 38
Metadata
- Authors
- Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S. D., & Chang, D. D.
- Affiliations
- Ghent University Hospital (BE)
- Amgen (United States) (US)
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca’ Granda, Milan, Italy
- Venue
- Journal of Clinical Oncology
- Published
- 2008-04-01
- Volume
- 26
- Issue
- 10
- Pages
- 1626-1634
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106789440
- Cited by
- 3,207
- References
- 38
- Citations by year
- 2026: 32 · 2025: 48 · 2024: 59 · 2023: 77 · 2022: 112 · 2021: 123 · 2020: 106 · 2019: 135 · 2018: 131 · 2017: 163 · 2016: 181 · 2015: 253 · 2014: 280 · 2013: 254 · 2012: 288
- FWCI
- 169.59
- Type
- journal article
- Language
- en
- Update notices
- new_edition (2023-06-14)
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- panitumumab, KRAS wild-type, KRAS mutation, metastatic colorectal cancer, anti-EGFR therapy, epidermal growth factor receptor, biomarker selection, progression-free survival, best supportive care, treatment toxicity, patient selection
- MeSH terms
- Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Proto-Oncogene Proteins, Biomarkers, Tumor, Colorectal Neoplasms, Polymerase Chain Reaction, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, Drug Resistance, Neoplasm, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
